Shandong Boyuan Pharmaceutical&Chemical
301617
FORSTAR
835640
Cre8 Direct(Ningbo)Co.,Ltd.
300703
Minami Acoustics
301383
ASR Microelectronics
688220
CN Stock MarketDetailed Quotes
300809 Hiecise Precision Equipment Co.,Ltd.
- 34.30
- +0.67+1.99%
Market Closed Dec 11 15:00 CST
8.70BMarket Cap109.24P/E (TTM)
35.15High33.11Low104.78KlotVolume34.01Open33.63Pre Close359.02MTurnover7.43%Turnover Ratio73.92P/E (Static)253.54MShares35.1552wk High5.44P/B4.84BFloat Cap17.6452wk Low40.36Limit Up141.11MShs Float42.69Historical High26.90Limit Down6.07%Amplitude8.29Historical Low0.12Dividend TTM34.26Avg Price51.58KlotAsk0.35%Div YieldTTM100Lot Size48.98KlotBid
Hiecise Precision Equipment Co.,Ltd. Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -16.23%292.73M | -9.52%224.43M | 21.29%124.64M | 42.48%479.16M | 44.79%349.46M | 58.95%248.03M | 19.25%102.76M | -17.86%336.31M | -26.03%241.36M | -37.89%156.04M |
| Operating revenue | -16.23%292.73M | -9.52%224.43M | 21.29%124.64M | 42.48%479.16M | 44.79%349.46M | 58.95%248.03M | 19.25%102.76M | -17.86%336.31M | -26.03%241.36M | -37.89%156.04M |
| Other operating revenue | ---- | -10.93%415.38K | ---- | -52.10%941.02K | ---- | -51.28%466.37K | ---- | -8.32%1.96M | ---- | -4.47%957.29K |
| Total operating cost | -7.64%258.17M | 1.31%192.6M | 23.98%103.66M | 40.63%386.8M | 35.54%279.53M | 45.67%190.1M | 27.89%83.61M | -17.65%275.06M | -14.37%206.23M | -27.23%130.5M |
| Operating cost | -10.41%205.01M | -1.20%156.3M | 23.04%85.04M | 40.31%314.82M | 51.13%228.82M | 62.35%158.2M | 41.33%69.12M | -12.94%224.37M | -22.78%151.41M | -35.22%97.45M |
| Operating tax surcharges | 33.12%2.3M | 36.05%1.64M | 167.64%860.53K | 6.56%2.38M | 12.70%1.72M | 4.00%1.2M | -2.23%321.53K | -41.50%2.23M | -46.97%1.53M | -47.14%1.16M |
| Operating expense | -14.15%13.44M | 5.15%9.55M | 35.48%4.86M | 14.89%19.62M | 29.59%15.65M | 42.26%9.08M | -10.30%3.58M | 4.70%17.07M | -2.11%12.08M | -10.97%6.39M |
| Administration expense | -9.01%16.4M | -6.43%12.05M | 9.85%6.63M | 16.98%26.83M | -0.23%18.03M | 10.80%12.88M | 5.74%6.03M | -10.50%22.94M | 49.96%18.07M | 46.07%11.62M |
| Financial expense | 22.58%-6.32M | 17.48%-5.25M | 50.68%-1.37M | 57.12%-10.46M | -757.40%-8.16M | -526.60%-6.36M | -356.80%-2.77M | -1,950.65%-24.39M | 13.48%1.24M | 68.39%1.49M |
| -Interest expense (Financial expense) | 203.53%441.3K | -19.02%117.74K | -57.64%38.39K | -19.09%278.46K | -41.19%145.39K | -40.55%145.39K | 4,796.32%90.63K | -75.17%344.18K | -79.82%247.24K | -73.79%244.57K |
| -Interest Income (Financial expense) | 21.15%-6.11M | 11.99%-4.93M | 53.89%-1.35M | 59.37%-10.7M | -1,441.17%-7.75M | -1,304.42%-5.61M | -1,182.43%-2.93M | -5,247.78%-26.33M | -44.80%-502.67K | -63.74%-399.15K |
| Research and development | 16.52%27.34M | 21.30%18.31M | 4.28%7.64M | 2.35%33.62M | 7.11%23.46M | 21.81%15.1M | 36.59%7.32M | 12.36%32.84M | 33.61%21.91M | 15.75%12.39M |
| Credit Impairment Loss | -66.56%5.9M | 104.87%6.89M | 38.88%5.86M | 160.94%21.33M | 169.41%17.63M | 222.16%3.36M | 120.62%4.22M | -95.84%-35M | -117.33%-25.4M | 171.26%1.04M |
| Asset Impairment Loss | -202.43%-8.69M | -1,327.48%-8.36M | -1,504.34%-5.94M | -27.26%-3.38M | 1,128.29%8.48M | 79.31%-585.76K | -384.01%-370.05K | 31.79%-2.66M | 112.10%690.45K | 41.12%-2.83M |
| Other net revenue | -37.58%29M | 166.54%21.09M | 1,953.03%10.67M | 1,072.94%47.04M | 780.02%46.46M | -3.43%7.91M | -93.93%519.9K | -131.60%-4.83M | -503.30%-6.83M | 85.91%8.19M |
| Fair value change income | 872.94%14.91M | 235.43%9.97M | 223.06%7.86M | -190.29%-9.14M | -181.45%-1.93M | -864.85%-7.36M | -291.81%-6.39M | 347.24%10.12M | 182.62%2.37M | -211.21%-763.31K |
| Invest income | -52.78%6.74M | -29.24%6.94M | -86.37%259.85K | 28.11%22.44M | 18.85%14.28M | 1.78%9.8M | -25.87%1.91M | -40.23%17.52M | 9.21%12.01M | 70.42%9.63M |
| Asset deal income | 33.79%-139.42K | -8.55%-139.42K | 67.49%-41.75K | -39.22%-130.82K | -124.08%-210.56K | -36.68%-128.44K | ---128.44K | -7,963.67%-93.97K | -7,963.67%-93.97K | ---93.97K |
| Other revenue | 25.09%10.28M | 104.80%5.79M | 108.19%2.66M | 201.25%15.91M | 128.65%8.22M | 133.96%2.83M | 106.98%1.28M | -55.42%5.28M | -67.20%3.59M | -72.16%1.21M |
| Operating profit | -45.39%63.56M | -19.63%52.91M | 60.89%31.66M | 147.07%139.4M | 311.43%116.39M | 95.17%65.83M | -33.00%19.68M | -37.83%56.42M | -67.53%28.29M | -55.78%33.73M |
| Add:Non operating Income | 474.80%80.49K | -98.07%270.21 | -100.00%0.19 | 12,715,181.30%292.45K | 1,443,437.11%14K | --14K | --14K | 105.36%2.3 | -13.39%0.97 | ---- |
| Less:Non operating expense | -57.75%443.34K | -88.52%93.2K | -99.88%934.53 | 178.77%1.52M | 99.29%1.05M | 54.21%811.82K | 38,751.30%761.18K | 51.77%543.59K | 61.95%526.47K | 135.58%526.45K |
| Total profit | -45.21%63.2M | -18.79%52.82M | 67.24%31.66M | 147.28%138.17M | 315.50%115.36M | 95.86%65.04M | -35.54%18.93M | -38.18%55.88M | -68.02%27.76M | -56.35%33.21M |
| Less:Income tax cost | -68.59%4.6M | -41.74%4.49M | 44.51%3.79M | 1,284.32%15.42M | 11,453.01%14.65M | 202.86%7.7M | -33.26%2.62M | -88.19%1.11M | -101.30%-129.01K | -74.47%2.54M |
| Net profit | -41.81%58.6M | -15.70%48.33M | 70.89%27.86M | 124.15%122.75M | 261.07%100.71M | 86.99%57.33M | -35.89%16.31M | -32.36%54.76M | -63.74%27.89M | -53.61%30.66M |
| Net profit from continuing operation | -41.81%58.6M | -15.70%48.33M | 70.89%27.86M | 124.15%122.75M | 261.07%100.71M | 86.99%57.33M | -35.89%16.31M | -32.36%54.76M | -63.74%27.89M | -53.61%30.66M |
| Less:Minority Profit | -88.33%540.61K | -82.21%675.15K | -45.01%728.37K | -33.77%5M | -21.69%4.63M | 17.20%3.8M | -19.56%1.32M | 72.27%7.55M | 63.74%5.91M | 43.52%3.24M |
| Net profit of parent company owners | -39.57%58.06M | -10.99%47.66M | 81.14%27.14M | 149.41%117.75M | 337.17%96.08M | 95.23%53.54M | -37.02%14.98M | -38.35%47.21M | -70.02%21.98M | -57.05%27.42M |
| Earning per share | ||||||||||
| Basic earning per share | -39.47%0.23 | -9.52%0.19 | 83.33%0.11 | 56.67%0.47 | 171.43%0.38 | 23.53%0.21 | -60.00%0.06 | -38.78%0.3 | -70.21%0.14 | -58.54%0.17 |
| Diluted earning per share | -39.47%0.23 | -9.52%0.19 | 83.33%0.11 | 56.67%0.47 | 171.43%0.38 | 23.53%0.21 | -60.00%0.06 | -38.78%0.3 | -70.21%0.14 | -58.54%0.17 |
| Other composite income | 4.42%-480.38K | -17.54%-345.84K | 14.45%-182.52K | 146.09%1.25M | 97.27%-502.57K | -101.06%-294.24K | -213.34K | 405.06%507.56K | -18.38M | -146.35K |
| Other composite income of parent company owners | 4.42%-480.38K | -17.54%-345.84K | 14.45%-182.52K | 146.09%1.25M | 97.27%-502.57K | -101.06%-294.24K | ---213.34K | 405.06%507.56K | ---18.38M | ---146.35K |
| Total composite income | -42.00%58.12M | -15.87%47.98M | 72.02%27.68M | 124.35%124M | 953.00%100.21M | 86.92%57.04M | -36.73%16.09M | -31.59%55.27M | -87.63%9.52M | -53.84%30.52M |
| Total composite income of parent company owners | -39.76%57.58M | -11.14%47.31M | 82.52%26.95M | 149.37%119M | 2,553.68%95.58M | 95.20%53.24M | -37.91%14.77M | -37.55%47.72M | -95.09%3.6M | -57.28%27.28M |
| Total composite income of minority owners | -88.33%540.61K | -82.21%675.15K | -45.01%728.37K | -33.77%5M | -21.69%4.63M | 17.20%3.8M | -19.56%1.32M | 72.27%7.55M | 63.74%5.91M | 43.52%3.24M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
